Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant

Gardasil
Proper Name: Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant
Tradename: Gardasil
Manufacturer: Merck & Co., Inc, License #0002
Indications:

Prevention of vulvar and vaginal cancer
Vaccination in females 9 to 26 years of age for prevention of the following diseases caused by Human Papillomavirus (HPV) Types 6, 11, 16, and 18:
Cervical cancer
Genital warts (condyloma acuminata) and the following precancerous or dysplastic lesions:
Cervical adenocarcinoma in situ (AIS)
Cervical intraepithelial neoplasia (CIN) grade 2 and grade 3
Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3
Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3
Cervical intraepithelial neoplasia (CIN) grade 1
Vaccination in boys and men 9 through 26 years of age for the prevention of genital warts caused by HPV types 6 and 11

abrir aquí para acceder al documento FDA y sus vínculos:
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094042.htm